Effect of EP4 agonist (ONO4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: A randomized phase II, placebo-controlled trial

Inflammatory Bowel Diseases

Volumn 16, Issue 5, 2010, Pages 731-733

  Nakase, Hiroshi ^a   Fujiyama, Yoshihide ^b   Oshitani, Nobuhide ^c   Oga, Toru ^a   Nonomura, Kimiko ^a   Matsuoka, Toshiyuki ^a   Esaki, Yoshiyasu ^a   Murayama, Toshinori ^a   Teramukai, Satoshi ^a   Chiba, Tsutomu ^a   Narumiya, Shuh ^c  

^a KYOTO UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c School of Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER; MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; COLONOSCOPY; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED HEADACHE; EOSINOPHIL; FEVER; FLOW CYTOMETRY; HISTOLOGY; HOT FLUSH; HUMAN; HYPOTENSION; LETTER; NEUTROPENIA; PATHOLOGIST; PRIORITY JOURNAL; SAMPLE SIZE; SIDE EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HEPTANOATES; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PLACEBOS; RECEPTORS, PROSTAGLANDIN E; TREATMENT OUTCOME;

EID: 77950646755     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21080     Document Type: Letter

References (8)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and function. Physiol Rev. 1999; 79: 1193-1226.
2. Nitta M., Hirata I, Toshina K, et al. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol. 2002; 56: 66-75.
3. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002; 109: 883-893.
4. 4. Sutherland LR, Martin F, Greer S, et al. 5Aminosalicyclic acid enema in the treatment of distal ulcerative colitis, protcosigmoiditis, and proctitis. Gastroenterology. 1987; 92: 1894-1898. (Pubitemid 17072238)
5. Hoshino T, Tsutumi S, Tomisato W, et al. Prostagalndin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem. 2003; 278: 12752-12758.
6. 6. Harizi H, Norbert G. Inhibition of IL-6, TNFα, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell Immunol. 2004; 228: 99-109. (Pubitemid 38813333)
7. Nakase H, Mikami S, Chiba T. Alteration of CXCR4 expression and Th1/Th2 balance of peripheral CD4-positive T cells can be a biomarker for leukocytapheresis therapy for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 963-964.
8. Yao C, Sakata D, Esaki Y, et al. Prostaglandin-E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med. 2009; 15: 633-640.